FDA grants Fast Track Designation for remestemcel-L in the treatment of acute respiratory distress syndrome due to COVID-19

Data to FDA supporting use of this investigational therapy comprising culture-expanded mesenchymal stromal cells include results from pilot study in which 9 of 12 ventilator-dependent patients were successfully discharged from hospital median of 10 days after receiving 2 IV doses

Source:

Biospace Inc.